The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

Amendment of regulation 259 (packaging requirements: information for blind and partially sighted patients)

Amendment of regulation 260 (package leaflets)

Amendment of Schedule 27 (package leaflets)

Amendment of regulation 266 (language requirements etc)

Amendment of regulation 267 (submission of mock-ups of packaging and leaflets to licensing authority)

Amendment of regulation 268 (offence relating to packaging and package leaflets)

Insertion of new regulation 268A (offence relating to packaging and package leaflets in Northern Ireland: holder of authorisation etc)

207A

After regulation 268 insert—

(268A) (1) This regulation applies to the holder of a UKMA(UK), UKMA(NI), EU marketing authorisation, Article 126a authorisation, certificate of registration or traditional herbal registration for a medicinal product who sells or supplies, offers to sell or supply, or possesses for the purpose of sale or supply, in Northern Ireland, a medicinal product to which the authorisation, certificate or registration relates. (2) A person to whom this regulation applies is guilty of an offence if— (a) a package or package leaflet relating to the product does not comply with the applicable requirements of this Part, Article 9 of Commission Regulation 2016/161 or Article 28 or 32 of the Paediatric Regulation; or (b) the product is not accompanied by a package leaflet when one is required by virtue of this Part.

Amendment of regulation 269 (offences relating to packaging and package leaflets: other persons)

Insertion of new regulation 269A (offences relating to packaging and package leaflets in Northern Ireland: other persons)

208A

After regulation 269 insert—

(269A) (1) This regulation applies to a person, other than the holder of a UKMA(UK), UKMA(NI), EU marketing authorisation, Article 126a authorisation, certificate of registration or traditional herbal registration for a medicinal product, who, in the course of a business carried on by that person, sells or supplies, or offers to sell or supply the product, or possesses the product for the purpose of sale or supply in Northern Ireland. (2) A person to whom this regulation applies is guilty of an offence if the person sells or supplies, or offers to sell or supply, the product, or possesses the product for the purpose of sale or supply, in Northern Ireland knowing or having reasonable cause to believe— (a) that a package or package leaflet relating to the medicinal product does not comply with the applicable requirements of this Part, Article 9 of Commission Regulation 2016/161 or Article 28 or 32 of the Paediatric Regulation; or (b) that the product is not accompanied by a package leaflet when one is required by virtue of this Part.

Amendment of regulation 270 (non-compliance with requirements of this Part)

Amendment of regulation 271 (offences: penalties)

209A

In regulation 271 for “268, 269” substitute “268, 268A, 269, 269A”.

Amendment of regulation 273 (child resistant containers for regulated medicinal products)

Insertion of new regulation 284A (Medicines with differing classification status in Great Britain and Northern Ireland)

213A

After regulation 284, insert—

(284A) In the case of a medicinal product for sale or supply in Great Britain where the product concerned is not a prescription only medicine in Great Britain but is either— (a) a prescription only medicine in Northern Ireland; or (b) not authorised for sale or supply in Northern Ireland, any advertisement to the public must include a statement that the medicinal product is not available without a prescription, or is not available for sale or supply, in Northern Ireland (as the case may be).

Amendment of regulation 293 (prohibition of supply to the public for promotional purposes)

Amendment of regulation 294 (general requirements)

214A

In regulation 294, after paragraph (4) insert—

(5) In the case of an advertisement which relates to a medicinal product for sale or supply— (a) in Northern Ireland only, the requirements of this regulation must be met in relation to the product for sale or supply in Northern Ireland, (b) in Great Britain only, the requirements of this regulation must be met in relation to the product for sale or supply in Great Britain, and (c) in the whole of the United Kingdom, the requirements of this regulation must be met in relation to both— (i) the product for sale or supply in Great Britain, and (ii) the product for sale or supply in Northern Ireland.

Amendment of regulation 295 (abbreviated advertisements)

Amendment of regulation 298 (free samples for persons qualified to prescribe or supply medicinal products)

215A

In regulation 298, for paragraph (5)(a) substitute—

(a) is no larger than the smallest presentation of the product that is available for sale— (i) in the case of a medicinal product for sale or supply in Great Britain, in Great Britain, or (ii) in the case of a medicinal product for sale or supply in Northern Ireland, in Northern Ireland;

Amendment of Schedule 30 (particulars for advertisements to persons qualified to prescribe or supply)

Amendment of regulation 299 (medical sales representatives)

Amendment of regulation 305 (invitation to make representations about compatibility)

217A

In regulation 305—

• (a) for paragraph (3)(a) substitute—

(a) state that the Ministers are minded to make a determination under regulation 306 that the advertisement is incompatible with the prohibitions imposed by Chapter 2 and specify whether the incompatibility is insofar as the advertisement is for publication— (i) in Great Britain; (ii) in Northern Ireland; or (iii) in both Great Britain and Northern Ireland;

• (b) in paragraph (4), after “the advertisement” insert—

— (a) in Great Britain; (b) in Northern Ireland; or (c) in both Great Britain and Northern Ireland

Amendment of regulation 306 (decision about compatibility)

217B

In regulation 306—

• (a) in paragraph (2), after “Chapter 2” insert—

and specify whether the incompatibility is insofar as the advertisement is for publication— (a) in Great Britain; (b) in Northern Ireland; or (c) in both Great Britain and Northern Ireland

• (b) in paragraph (4)—

• (i) in sub-paragraph (a), after “Chapter 2” insert—

insofar as the advertisement is for publication— (i) in Great Britain; (ii) in Northern Ireland; or (iii) in both Great Britain and Northern Ireland

• (ii) after “no longer applies” insert “in Great Britain, Northern Ireland, or both Great Britain and Northern Ireland (as appropriate)”;

• (c) in paragraph (5), after “Chapter 2” insert—

insofar as the advertisement is for publication— (a) in Great Britain; (b) in Northern Ireland; or (c) in both Great Britain and Northern Ireland

• (d) in paragraph (7)(b), after “no longer applies” insert—

• , and where that original notice related to both Great Britain and Northern Ireland, the new notice may be expressed to apply in relation to either of or both Great Britain and Northern Ireland

• (e) in paragraph (8), after “the advertisement” insert—

— (a) in Great Britain; (b) in Northern Ireland; or (c) in both Great Britain and Northern Ireland

Amendment of regulation 307 (corrective statement)

217C

In regulation 307—

• (a) in paragraph (1)(a), after “subject of the notice” insert—

in— (i) Great Britain; (ii) Northern Ireland; or (iii) both Great Britain and Northern Ireland

• (b) in paragraph (1)(b), after “that advertisement” insert—

in— (i) Great Britain; (ii) Northern Ireland; or (iii) both Great Britain and Northern Ireland

• (c) in paragraph (2)(a), for “, either in full or in part; and” substitute—

in respect of— (i) Great Britain; (ii) Northern Ireland; or (iii) both Great Britain and Northern Ireland, either in full or in part; and

Amendment of regulation 311 (application for injunction)

217D

In regulation 311—

• (a) in paragraph (1)(a), for “Chapter 2; and” substitute—

Chapter 2 in respect of— (i) Great Britain; (ii) Northern Ireland; or (iii) both Great Britain and Northern Ireland; and

• (b) in paragraph (3), after “ the advertisement” insert—

in— (i) Great Britain; (ii) Northern Ireland; or (iii) both Great Britain and Northern Ireland, as the case may be.

Amendment of regulation 335 (contravention due to fault of another person)

224ZA

In regulation 335(6)(b) for “268 and 269” substitute “268, 268A, 269 and 269A”.

Amendment of regulation 336 (warranty as defence)

224ZB

In regulation 336(3)(b) for “268 and 269” substitute “268, 268A, 269 and 269A”.

Amendment of regulation 340 (presumptions)

224ZC

In regulation 340(5) for “268 (offences relating to packaging and package leaflets: authorisation holders), 269 (offences relating to packaging and package leaflets: other persons)” substitute “268 (offences relating to packaging and package leaflets in Great Britain: authorisation holders), 268A (offences relating to packaging and package leaflets in Northern Ireland: authorisation holders), 269 (offences relating to packaging and package leaflets in Great Britain: other persons), 269A (offences relating to packaging and package leaflets in Northern Ireland: other persons)”.

Amendment of Schedule 32 (transitional provisions and savings)

224ZD

In paragraph 3(10) of Schedule 32 for “268 (offences relating to packaging and package leaflets: authorisation holders), 269 (offences relating to packaging and package leaflets: other persons)” substitute “268 (offences relating to packaging and package leaflets in Great Britain: authorisation holders), 268A (offences relating to packaging and package leaflets in Northern Ireland: authorisation holders), 269 (offences relating to packaging and package leaflets in Great Britain: other persons), 269A (offences relating to packaging and package leaflets in Northern Ireland: other persons)”.

Amendment of regulation 341 (decisions under the Human Medicines Regulations 2012)

Insertion of regulation 344A (modifications to deal with serious shortages) and 344B (regulation making powers)

Amendment of regulation 345 (immunity from civil liability)

Amendment of regulation 346 (Secretary of State to carry out a review of certain provisions)

Insertion of new regulation 10A (waiver for advice given to small and medium companies)

1ZA

After regulation 10 insert—

(10A) (1) The fee payable in connection with a meeting mentioned in any of regulations 4 to 10 is waived where the person by whom the fee would otherwise be payable is established in the United Kingdom and is— (a) a small company, or (b) a medium-sized company. (2) In this regulation, “small company” and “medium-sized company” have the same meanings as in sections 382 and 465 of the Companies Act 2006 respectively.

Amendment of regulation 19 (capital fees for applications for variations of authorisations)

Insertion of regulations 19A-19F (fees for plasma master files, vaccine antigen master files, post-authorisation safety studies, major safety reviews, periodic safety update reports and batch testing)

Amendment of regulation 23 (applications for multiple variations)

Insertion of regulation 27A (fee for renewals of a marketing authorisation)

Omission of Part 8 (Capital Fees for Regulatory Assistance Given by the United Kingdom Acting as Reference Member State Relating to the Assessment of Applications for the Renewal of Specified Marketing Authorisations)

Amendment of Schedule 1 (general interpretation provisions)

Amendment of Schedule 2 (capital fees for applications for, and variations to, marketing authorisations, licences, registrations and certificates)

Amendment of Schedule 4 (periodic fees for licences)

Amendment of Schedule 6 (time for payment of capital fees: small companies)

8A

In Schedule 6, in paragraph 2, for “entry 1(f)” substitute “entry 1(h)”.

Amendment of Schedule 7 (waiver, reduction or refund of capital fees)

Amendment of Schedule 8 (Adjustment, reduction or refund of periodic fees)

Savings

SCHEDULE2A — Insertion of new Schedule 8C (Material to accompany an application for a UK marketing authorisation under the unfettered access route)

1

After Schedule 8B to the Human Medicines Regulations 2012, insert—

SCHEDULE8C (1) A copy of the application submitted in connection with the granting of the EU marketing authorisation or UKMA(NI) which authorises the sale or supply of the medicinal product in Northern Ireland. (2) A copy of all material submitted in support of the application for the EU marketing authorisation or UKMA(NI) which authorises the sale or supply of the medicinal product in Northern Ireland. (3) A copy of the EU marketing authorisation or UKMA(NI) which authorises the sale or supply of the medicinal product in Northern Ireland.

Editorial notes

[^c23884261]: 2018 c. 16.

[^c23884271]: S.I. 2012/1916.

[^c23884281]: S.I. 2016/190.

[^c23884301]: Regulation 8 was amended by S.I. 2013/1855 and 2593, 2015/1503, 2016/186, 190 and 696, 2017/715, 2018/199 and 2019/62.

[^c23884311]: S.I. 2002/618. It was amended by S.I. 2008/2936.

[^c23884321]: Regulation 137 is inserted by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019.

[^c23884331]: OJ No. L 106, 17.4.2001, p. 1, as last amended by Commission Directive (EU) 2018/350.

[^c23884341]: Regulation 69 is inserted by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019.

[^c23884351]: OJ No. L 018, 22.01.2000, p. 1.

[^c23884361]: 1977 c. 37. Section 128B was inserted by S.I. 2007/3293 and subsection (2) was amended by S.I.2014/2411.

[^c23884371]: The definition of “import” was inserted by S.I. 2013/1855.

[^c23884381]: The definition of “care home” was inserted by S.I. 2019/62.

[^c23884421]: Paragraph (8) was inserted by S.I. 2013/1855.

[^c23884431]: Regulation A17 was inserted by S.I. 2013/1855.

[^c23884441]: The principles and guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c23884451]: Regulation 18 was substituted by S.I. 2013/1855 and further amended by S.I. 2016/186.

[^c23884461]: Regulation 19 was amended by S.I. 2013/1855.

[^c23884471]: 1990 c. 37. Schedule 3A was inserted by the Human Fertilisation and Embryology (Quality and Safety) Regulations 2007/1522, regulation 30.

[^c23884481]: S.I. 2007/1523.

[^c23884491]: Schedule 5 was amended by S.I. 2013/1855.

[^c23884501]: S.I. 2005/50. It was amended by S.I. 2005/1098 and 2898, 2006/2013, 2007/604, 2008/525 and 941, 2009/372 and 3307, 2010/554, 2016/604, 2017/1320 and 2018/231.

[^c23884511]: Sections 33A to 33D were inserted by the Human Fertilisation and Embryology Act 2008, c. 22.

[^c23884531]: Regulation 37 was substituted by S.I. 2013/1855.

[^c23884541]: S.I. 2005/50. It has been amended by S.I. 2005/1098 and 2898, 2006/2013, 2007/604, 2008/525 and 941, 2009/372 and 3307, 2010/554, 2016/604, 2017/1320 and 2018/231.

[^c23884551]: Regulation 38 was amended by S.I. 2015/1503.

[^c23884561]: Regulation 39 was amended by S.I. 2013/1855, 2015/354 and 2019/62.

[^c23884571]: Regulation 42 was amended by S.I. 2013/1855 and 2019/62.

[^c23884581]: Schedule 7 was amended by S.I. 2019/62.

[^c23884591]: Regulation 43 was amended by S.I. 2013/1855 and 2016/186.

[^c23884611]: Regulation 44 was amended by S.I. 2013/1855, 2015/1503 and 2016/186.

[^c23884621]: Regulation 45A was inserted by S.I. 2013/1855.

[^c23884631]: Regulation 45D was inserted by S.I. 2013/1855.

[^c23884641]: Regulation 45E was inserted by S.I. 2013/1855.

[^c23884651]: Regulation 45F was inserted by S.I. 2013/1855.

[^c23884661]: Regulation 45M was inserted by S.I. 2013/1855.

[^c23884671]: Schedule 7A was inserted by S.I. 2013/1855.

[^c23884681]: Regulation 45O was inserted by S.I. 2013/1855.

[^c23884691]: Regulation 48 was amended by S.I. 2014/1878.

[^c23884701]: Regulation 49 was amended by S.I. 2014/1878.

[^c23884711]: 2006 c.46.

[^c23884721]: Regulation 50 was amended by S.I. 2014/1878.

[^c23884731]: The guidance is available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c23884741]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c23884751]: The guidance is available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c23884761]: Schedule 8 was amended by S.I. 2013/1855.

[^c23884771]: Schedule 8A was inserted by S.I. 2014/1878.

[^c23884781]: S.I. 2002/618, as amended by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019.

[^c23884791]: S.I. 2002/2443, as amended by S.I. 2004/2411.

[^c23884801]: S.I. 2002/3188, as amended by S.I. 2005/1913.

[^c23884811]: S.S.I. 2002/541, as amended by S.S.I. 2004/439.

[^c23884821]: S.R. 2003/167, as amended by S.R. 2005/272.

[^c23884851]: S.I. 2002/618, as amended by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019.

[^c23884861]: Regulation 59 was amended by S.I. 2014/1878.

[^c23884871]: 2012 c.7.

[^c23884881]: Regulation 65A was inserted by S.I. 2014/1878.

[^c23884891]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c23884901]: Regulation 66A was inserted by S.I. 2014/1878.

[^c23884911]: Regulation 68 was amended by S.I. 2013/1855 and 2014/1878.

[^c23884921]: Regulation 69 was amended by S.I. 2014/1878.

[^c23884931]: Regulation 71 was amended by S.I. 2014/1878.

[^c23884941]: Regulation 73 was amended by S.I. 2013/2593: regulation 3 inserted sub-paragraphs (5A) to (5C).

[^c23884951]: Regulation 75 was amended by S.I. 2014/1878.

[^c23884971]: 1990 c. 37. Sections 33A to 33D were inserted by the Human Fertilisation and Embryology Act 2008, c. 22.

[^c23884981]: S.I. 2005/50. It was amended by S.I. 2005/1098 and 2898, 2006/2013, 2007/604, 2008/525 and 941, 2009/372 and 3307, 2010/554, 2016/604, 2017/1320 and 2018/231.

[^c23884991]: S.I. 2007/1523.

[^c23885031]: Regulation 97 was substituted by S.I. 2014/1878.

[^c23885051]: Regulation 110 was amended by S.I.2013/1855.

[^c23885061]: Paragraph (3A) was inserted by S.I. 2013/2593.

[^c23885071]: Regulation 135 was amended by S.I. 2013/1855.

[^c23885081]: Regulation 142 was amended by S.I. 2013/2593.

[^c23885091]: Regulation 177 was amended by S.I. 2013/1855 and 2014/1878.

[^c23885101]: Regulation 182 was amended by S.I. 2013/1855.

[^c23885111]: Regulation 195 was amended by S.I. 2014/1878.

[^c23885131]: Regulation 206 was amended by S.I. 2013/1855.

[^c23885151]: Regulation 210A was inserted by S.I. 2013/1855.

[^c23885161]: Regulation 213 was amended by S.I. 2013/235 and 2014/490 and 1878.

[^c23885171]: The definition was substituted by S.I. 2014/1878.

[^c23885181]: Regulation 214 was amended S.I. 2013/1855, 2014/490, 2016/186 and 2018/199.

[^c23885191]: Regulation 217 was amended by S.I. 2014/490.

[^c23885201]: Regulation 217A was inserted by S.I. 2014/490.

[^c23885211]: Regulation 218 was amended by S.I. 2014/490 and 1878 and 2015/903.

[^c23885221]: Regulation 219 was amended by S.I. 2015/903 and 2016/696.

[^c23885231]: Regulation 219A was amended by S.I. 2015/903.

[^c23885281]: Schedule 17 was amended by S.I. 2014/1878, 2015/1503, 2016/186 and 2017/715,

[^c23885291]: 1990 c. 37. Sections 33A to 33D were inserted by the Human Fertilisation and Embryology Act 2008, c. 22.

[^c23885301]: S.I. 2005/50. It has been amended by S.I. 2005/1098 and 2898, 2006/2013, 2007/604, 2008/525 and 941, 2009/372 and 3307, 2010/604, 2017/1320 and 2018/231.

[^c23885311]: S.I. 2007/1523.

[^c23885371]: 1990 c. 37. Schedule 3A was inserted by the Human Fertilisation and Embryology (Quality and Safety) Regulations 2007/1522, regulation 30.

[^c23885381]: S.I. 2007/1523.

[^c23885391]: Schedule 27 was amended by S.I. 2014/1878.

[^c23885401]: Regulation 268 was amended by S.I. 2019/62.

[^c23885411]: Regulation 269 was amended by S.I. 2015/903 and 2019/62.

[^c23885431]: Regulation 323 was amended S.I. 2019/62.

[^c23885441]: Regulation 327 was amended by S.I. 2013/1855 and 2019/62.

[^c23885451]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c23885461]: Regulation 346 was substituted by S.I. 2013/1855 and then amended by S.I. 2013/2593, 2014/490 and 1878, 2015/323, 903 and 1503, 2016/186, 2017/715, 2018/199 and 2019/62.

[^c23885471]: Section 465 was amended by S.I. 2015/980

[^c23885481]: S.I. 2002/2677

[^c23885491]: S.I. 2004/1157.

[^c23885501]: S.I. 1999/3106.

[^c23885511]: 1986 c. 14, as amended by S.I. 2012/3039.

[^c23885521]: S.I. 2004/1157.

[^c23885531]: S.I. 2002/618.

[^c23885541]: S.I. 2005/50.

[^c23885551]: S.I. 1999/3106.

[^c23885561]: 1990 c. 37.

[^c23885571]: S.I. 2007/1523.

[^c23885581]: S.I. 2005/50.

[^c23885591]: S.I. 2002/618.

[^c23885601]: International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997; 336:309-15.

[^c23885611]: OJ No. L 387, 27.12.2006, p. 1.

[^c23885621]: OJ No. L 92, 30.3.2006, p. 6.

[^c23885631]: 2018 c. 12.

[^c23885641]: 2006 c.41.

[^c23885651]: S.I. 2012/1916.

[^c23885661]: 2016 c.9.

[^c23885671]: S.I. 1977/670. Article 2 was amended by S.I. 1990/2487, 1997/856, 2008/548 and 2012/1809.

[^c23885681]: S.I. 1997/1830. Article 5(1) was amended by S.I. 2012/1916.

[^c23885691]: S.I. 2001/1841.

[^c23885701]: Article 1 was amended by S.I. 2008/548 and 2012/1809.

[^c23885711]: Article 4 was amended by S.I. 2008/548 and 2012/1916.

[^c23885721]: S.I. 2002/3170.

[^c23885731]: Article 1 was amended by S.I. 2008/548 and 2012/1809.

[^c23885741]: Article 3 was amended by S.I. 2008/548 and 2012/1916.

[^c23885761]: S.I. 2005/50. Regulation 1A was inserted by S.I. 2019/4.

[^c23885771]: S.I. 2007/2785. Regulation 3(1)(a) was substituted by S.I. 2018/352.

[^c23885781]: S.I. 2008/548.

[^c23885791]: Article 1 was amended by S.I. 2012/1809.

[^c23885801]: Article 3 was amended by S.I. 2012/1916.

[^c23885811]: S.I. 2013/349.

[^c23885821]: S.I. 2014/1663.

[^c23885831]: S.I. 2015/895.

[^c23885841]: S.R. 2015 No. 339.

[^c23885851]: S.I. 2018/677.

[^c23885861]: S.I. 2018/345.

[^c23885871]: S.I. 2012/1916.

[^c23885881]: OJ No, L 189, 27.6.2014, p. 112.

[^key-2ade7f07f7821c7a77db45750561654f]: Reg. 30 in force on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-e818b4c40e421e0671fa662216229864]: Reg. 123 in force on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1211fecbdffda666199672934c6573d3]: Reg. 182 in force on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-11edcb445ed14d654aaeed144e46d41e]: Reg. 1 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-feffc30c14637dda5d28215a403e54c6]: Sch. 1 para. 1 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1f79cf7a90e5e42a9459abe88f6bad0f]: Sch. 1 para. 11 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-ed090aa8240f7ce9b0a44052c1d0aacf]: Sch. 1 para. 2 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-90dcb442961ddf4e6d26c30223d6ce1b]: Sch. 1 para. 3 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d97da7391e324657e70329441981eedb]: Sch. 1 para. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-227ec5160e7fc62651fc050720150df8]: Sch. 1 para. 5 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1210d621a9d4941865ca523cdd192693]: Sch. 1 para. 6 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-7883beb5ff056aeee6300cf1e7986e8d]: Sch. 1 para. 7 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-916f585221ed683dde92f0bddef5f637]: Sch. 1 para. 8 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5026188a46f2e9584c0b0334fdf563fa]: Sch. 1 para. 9 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5a5edfd4dff73044f16c4e2625b45909]: Sch. 1 para. 10 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-610766cac446371c16ded12affc54603]: Sch. 8 para. 1 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f3a9929d93d75ce19e07c42b8b648632]: Sch. 8 para. 2 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-0ae9c2b346fb6d486bf0fb61050e642d]: Sch. 8 para. 3 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-49826c6e851157cc1d1e8991404478e0]: Sch. 8 para. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-451b7c2c26374a12988c7f9a0a6bfc11]: Sch. 8 para. 5 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-888a30d85b959400a0803cd89c71eaa5]: Sch. 8 para. 6 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d14e218a4c8943329aeb4caf0111818c]: Sch. 8 para. 8 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5e71f64ff26d4e74e0e9ca373b877134]: Sch. 8 para. 9 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f154876fb5a2d615812abc0b98a1c15f]: Sch. 8 para. 10 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-44aba4f674efb993e8cc3eaeb7baa108]: Sch. 8 para. 11 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5bd9c3a8693a0c35ab4d68e6dec2067f]: Sch. 8 para. 12 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-a26de02a00b048aa63987d7b92b0640c]: Sch. 8 para. 13 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-8d6a9e91e17c5f8d8a6bdc59d86760d2]: Sch. 8 para. 14 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-285f667f7c0bcdeda1b394d0c64172ef]: Sch. 8 para. 15 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-3b31c876572adcb273690e2aacbe6cfc]: Sch. 8 para. 16 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-fb3fc7b6c1b693eb769758476fd13d15]: Sch. 9 para. 1 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5174bfe08e6de8ac207bdd4e2d914f3a]: Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-ebee5648fc1e93ed0034fa681bc0af12]: Reg. 5 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-ee37b274e61b3192a226ccad3f8e4521]: Reg. 7 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d671bb51636553a332e92c9833201114]: Reg. 10 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-37c673595d06b85243ebe3ba92a4bff2]: Reg. 13 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-117b5189b1dbd7ee754de663d4b576c6]: Reg. 14 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5732ef2af8c768619194b7143da4dae9]: Reg. 15 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-c1b0379e5560d97b128d237e4b1e1c5e]: Reg. 16 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-562b071e8eb325c8d0bf3789183707b4]: Reg. 17 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-9dd279cee6e544488e60c29d8119df7f]: Reg. 18 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-320687cdbcab75d8d62cb9abb574dcf8]: Reg. 19 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-401613f3af86833a33e3ada61263ae1e]: Reg. 20 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-11ba4945e2e68e5728b9bdd6b73f9985]: Reg. 22 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-c912040e05686f5a14751a3f58a62872]: Reg. 23 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-3e8c482f5028b4e6a2976be70ddc4224]: Reg. 24 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-10eceb19a8e1f10121350c671ef52068]: Reg. 25 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-0fd0744be8624a911d3c72f727398e45]: Reg. 26 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-7d362e59eb5f9e76d713b5a6f12d2ad4]: Reg. 27 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-be37d4673a219b977511d701badf3cf3]: Reg. 28 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-da76f6434c32268253c61002d079689e]: Reg. 29 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-66ba8b511c8050cc61644cdb69fc0501]: Reg. 32 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-67a70855f90016c52a8122c64d53e1c6]: Reg. 33 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-88c52dee63783edc6c046d0f80a09633]: Reg. 35 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-ca05765a3e33b1a8f836ad69379853d8]: Reg. 36 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-3b6b496a49bd708c70c6d4e5476ce453]: Reg. 37 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-9233c6504b25d9908b9e387d761f9c3f]: Reg. 38 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-e8f48c1cb6c6f0096e015b49da07920f]: Reg. 39 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d1e2fa24ed413b7b3f0cd0714f57e7ac]: Reg. 40 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5f213599c51b94b1c44c79fc11bf5fb9]: Reg. 41 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-e882919b83a9e71910130ada5bd3f0cb]: Reg. 42 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-07dd01498f7c405b1e8e667886193a61]: Reg. 43 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-09569054129e9558a0becd967a266e07]: Reg. 44 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d14007fa5e01e5448641ede7fe74d494]: Reg. 45 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f02f3c7cc437274dc24bfa3c02090fed]: Reg. 46 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f3feba98a8698b783a7a75c60e7a00b0]: Reg. 47 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-90f5014bf21aaa983b44359208b9b9dd]: Reg. 48 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-a4da07fef8ebcab77b03b31acf879979]: Reg. 49 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-c39fdd13ef76187e1692c6dfc39608fc]: Reg. 50 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5d10a6a688e2b258854886d65e7ec327]: Reg. 51 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-ed4bf285cc843095728600143a635129]: Reg. 52 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-4b5f2006955fed98de192a6f6c0405cf]: Reg. 53 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-e2d38149f773d22ecf1e6def75ad806a]: Reg. 55 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1fb259e2839c51fc9740d72bbca3c74e]: Reg. 59 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1a3566c226338c4ef583dc6ebe91c922]: Reg. 61 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-57c0f2a8caef006ca75a65fd978dff3d]: Reg. 62 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-b2fb1e4c603b2f88ba094f3439ac23ac]: Reg. 63 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-703436d7c7788524bcc924572762edfa]: Reg. 64 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-26c57068723e40bd942d6bcf7984e8f8]: Reg. 65 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-6b70e7ec11b0feea37aeff4ee38a5bad]: Reg. 67 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-bbd99fd9659dd0933c0fd12eacdf27bb]: Reg. 68 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-492f9f05b510952e1058ff717058fa0a]: Reg. 70 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-43af0071faa4bf23366604305d08ff00]: Reg. 71 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-425be3565009585eedb5693fc3a28201]: Reg. 72 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-dbd68088c702825a01c747b79dd78155]: Reg. 74 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1d29ddcccb704f16081b85a92158542b]: Reg. 75 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-14acc07fc6d8fe04f11565cdbbe69a2f]: Reg. 76 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-a885955c19b3dd73df5e4c45a71f5df0]: Reg. 77 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-0b983ab1ce6eef1c38c6cab110f82c55]: Reg. 78 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-08119f3b3ac3f52b6cb67737dd52485c]: Reg. 79 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-966fed21abc13af11d0710b218c5dd69]: Reg. 80 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-7aee830fe99fd36513dd1005bf4306d0]: Reg. 82 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-dcddaac9bb6fb29df3e6ba27cd1ba6c9]: Reg. 83 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-87768a07bdbb28c48feb43b84d787a88]: Reg. 87 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-00f5a7f92beaefcce45c31b21f7dbca3]: Reg. 89 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-bffd94be08e3f757a113c0599c51371f]: Reg. 94 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-6c9ed0fed5981bd6ad637803855bf8e0]: Reg. 98 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-8c8a318da96726e94d11e5c588ddd255]: Reg. 99 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-ea602d51b6dca6bb8fdc16aa660d61a6]: Reg. 101 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-6360865af19c8b92f3ad68fd51387865]: Reg. 102 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-0af929895299446b1cc01bc353f2bafa]: Reg. 103 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-7cf5d25d6e9cf5f7b2950a96a01844bd]: Reg. 104 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f543ea25d9530620a0388e1eff22459a]: Reg. 105 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-b08fb2453f8b60d62025ad332358897d]: Reg. 106 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-abc619d173101c2fe535c166db1821a4]: Reg. 108 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d16a653c8cf9ffe1f1a9563e6bc0872f]: Reg. 109 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d34cab9d5f5229aa797688b01f098910]: Reg. 110 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f14bad07d82e589b5c19b3f27309614e]: Reg. 111 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-55eadb4736f2a4db6e3438b4ea1822a0]: Reg. 112 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-422f408e91be1e4d6d086a4934fb9b7c]: Reg. 115 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d9afb76e54f3b89edf8e16deeeb9c530]: Reg. 116 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-6c647751f0f69c4d49d7b9b8e2d1a4e6]: Reg. 117 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-2c9e0330e603ad54bb7286d042031560]: Reg. 118 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-5dfc1ff4fdfa0a6d9b1b2b01446d50da]: Reg. 119 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-8040a842b41de2bb212171fde65be0c7]: Reg. 120 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-29649b9028e68db36b6a125aff4bc51c]: Reg. 121 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-d7771280210b2fbe00191dbdd81a9c41]: Reg. 122 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-09f8ffee79544dbd9f393338a64b476d]: Reg. 124 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-73fff87c48f6df91de6ff6b5320a9004]: Reg. 125 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-10ac4b8c715a007298ad53e75d319628]: Reg. 126 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-cb39fc0d4211916cb3d5ee220fa4488e]: Reg. 128 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-3ef1f0d0a062b1d0babea3b61b54f246]: Reg. 130 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-a180d183e397ff59de6de5eb2b78d443]: Reg. 133 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-0d32cf5151dc177e760edf466270b337]: Reg. 134 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-1eacbf9a278293ed785f85e55b1f980c]: Reg. 136 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-77ca4520bf41fad969791e124b61ac9c]: Reg. 137 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-77f0e3f23d43b56ce10cee218ac55157]: Reg. 138 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1